Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S

Open source

DOI
10.1007/s10637-017-0476-6
Published
2017 Dec
Container
Investigational new drugs
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10637-017-0476-6,
  title = {Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.},
  author = {Heidelberger V and Goldwasser F and Kramkimel N and Jouinot A and Franck N and Arrondeau J and Guégan S and Mansuet-Lupo A and Alexandre J and Damotte D and Avril MF and Dupin N and Aractingi S},
  year = {2017},
  journal = {Investigational new drugs},
  doi = {10.1007/s10637-017-0476-6},
  url = {https://doi.org/10.1007/s10637-017-0476-6}
}

RIS

TY  - JOUR
TI  - Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.
AU  - Heidelberger V
AU  - Goldwasser F
AU  - Kramkimel N
AU  - Jouinot A
AU  - Franck N
AU  - Arrondeau J
AU  - Guégan S
AU  - Mansuet-Lupo A
AU  - Alexandre J
AU  - Damotte D
AU  - Avril MF
AU  - Dupin N
AU  - Aractingi S
PY  - 2017
JO  - Investigational new drugs
DO  - 10.1007/s10637-017-0476-6
UR  - https://doi.org/10.1007/s10637-017-0476-6
ER  - 

APA

V, H., F, G., N, K., A, J., N, F., J, A., S, G., A, M., J, A., D, D., MF, A., N, D., & S, A. (2017). Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.. Investigational new drugs. https://doi.org/10.1007/s10637-017-0476-6

Source records